Dedicated to Reimbursement Services and Patient Support

Nutropin GPS™ (Growing Patient Support) offers you and your patients assistance through every step of treatment from a dedicated case manager. Following the decision to prescribe growth hormone therapy, GPS services include device and injection training, insurance process management, a nurse hotline, and ongoing patient access and support programs. Call 1‐866‐NUTROPIN (1‐866‐688‐7674) to get started.

  • Nutropin GPS Provider Portal

    A password-protected portal that allows you to track patient status.

  • Priority Review

    Check if Nutropin AQ® [somatropin (rDNA origin) injection] is available on a patient’s formulary within one working day.

  • NuAccess

    A program providing medicine for pediatric patients while their insurance coverage is being evaluated.

Nutropin GPS Provider Portal

Nutropin GPS offers the password-protected Nutropin GPS Provider Portal to allow you to:

  • Complete a Statement of Medical Necessity (SMN) form online
  • Monitor your patients’ progress from the first SMN submission through the end of therapy
  • Access reports on patient status that are updated daily
  • Manage prescriptions and reauthorizations
  • Securely communicate with your dedicated case manager

View the Portal

Priority Review

Use Priority Review to check if Nutropin AQ is available on formulary. This service provides benefit verification within one working day. Check off "Priority Review" and complete the bolded fields on the Statement of Medical Necessity (SMN) to request this service.

Pediatric SMN Adult SMN Pediatric Nephrology SMN

Patient Access and Assistance Programs

Genentech is committed to helping your patients receive the treatment and medications they need. To this end, we provide a broad range of patient access and assistance programs, including:

Patient: Can I receive assistance while I wait for insurance approval?

NuAccessSM Program

A program providing medicine for pediatric patients while their insurance coverage is being evaluated.

  • New patients may receive Nutropin AQ NuSpin through the appeals process for up to 1 year
  • Existing patients may receive NuSpin or Nutropin AQ Pen for up to 30 days plus 2 refills
  • Patients must meet medical criteria for initial and subsequent requests
  • Product will be delivered to the patient’s home by a Genentech-designated pharmacy

Check off NuAccess on the SMN form and fax to your GPS case manager at (800) 545-0612 to start the process.

Pediatric SMN Adult SMN Pediatric Nephrology SMN

Patient: My insurance covers Nutropin, but can I receive help with my co-pay?

Nutropin GPSTM Co-Pay Card Program

Genentech offers the Nutropin GPS Co-pay Card to help qualified patients with the out-of-pocket costs associated with their Nutropin AQ prescription.*

Download the Program Brochure

*In order to qualify for the Nutropin Co-pay Card, the patient may be required to pay certain out-of-pocket expenses for each treatment. The Co-pay Card program is not valid for patients whose prescription drugs are covered, in whole or in part, under Medicaid, Medicare, or any other state or federal healthcare program. Patient or guardian is responsible for reporting the receipt of all Co-pay benefits or reimbursement received, to any insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the Co-pay Card program. This card is not health insurance or a benefit plan. You must be 18 years or older to receive Co-pay assistance for yourself or a minor. This Co-pay Card program is void if the card is reproduced and where prohibited by law. It is good only for Genentech products in the U.S. and Puerto Rico. The Co-pay Card program expires within 12 months from enrollment. Company reserves the right to rescind, revoke, or amend the program without notice at any time. Patient, guardian, pharmacist, prescriber and any other person using the Co-pay Card agree not to seek reimbursement for all or any part of the benefit received by the recipient through the offer. Additional Terms & Conditions apply. Please download the program brochure for the full list of Terms & Conditions.

Patient: What other co-pay support options are available to me?

Co-Pay Assistance Foundations

If privately or publicly insured patients have difficulty paying for their Nutropin AQ co-pay, co-insurance, or other expenses, Nutropin GPS can refer them to a co-pay assistance foundation* that supports their disease state. For more information, contact Genentech at 1-866-688-7674.

*Genentech does not influence or control the operations of these co-pay assistance foundations, but Nutropin GPS can assist patients in navigating the process of seeking co-pay assistance by making an appropriate referral based on a patient’s diagnosis and by assisting with the application process. We cannot guarantee co-pay assistance once a patient has been referred by Nutropin GPS. The foundations to which we refer patients each have their own criteria for patient eligibility, including financial eligibility.

Patient: I have no insurance or Nutropin is not covered by my plan. Can you help?

Genentech Access to Care Foundation (GATCF)

GATCF was established to help patients with unmet medical needs who are uninsured or rendered uninsured by payer denial and who meet specific financial and medical criteria to receive Nutropin AQ free of charge.

Access GATCF Forms to Get Started

Indications

Nutropin therapy is indicated for the treatment of pediatric patients who have short stature or growth failure as a result of:

  • Growth hormone deficiency (GHD)
  • Idiopathic short stature (ISS), defined by height standard deviation score ≤-2.25, associated with growth rates unlikely to result in normal adult height, in whom other causes of short stature have been excluded
  • Turner syndrome (TS)
  • Chronic kidney disease (CKD) up to the time of renal transplantation

Nutropin therapy is indicated for the replacement of endogenous GH in adults with GH deficiency, either:

  • Adult-onset, as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or
  • Childhood-onset. Patients treated for GH deficiency in childhood who have closed epiphyses should be reevaluated

Important Safety Information

CONTRAINDICATIONS

  • Acute critical illness: Somatropin should not be used to treat patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure. A significant increase in mortality has been reported in such cases
  • Prader-Willi syndrome (PWS) in children: Somatropin should not be used in pediatric patients with PWS who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death after initiation of somatropin treatment in such patients. Nutropin AQ is not indicated for the treatment of pediatric patients who have growth failure due to genetically confirmed PWS
  • Active malignancy: Somatropin is contraindicated in patients with any evidence of active malignancy. Growth hormone deficiency may be an early sign of a pituitary tumor or other intracranial tumor; the presence of such a tumor should be excluded before initiation of somatropin treatment
  • Diabetic retinopathy: Somatropin is contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy
  • Closed epiphyses: Somatropin should not be used for growth promotion in pediatric patients with closed epiphyses
  • Hypersensitivity: Nutropin therapy is contraindicated in patients with a known sensitivity to somatropin or excipients. Localized reactions are the most common hypersensitivity reactions

WARNINGS AND PRECAUTIONS

  • Patients with a history of GHD secondary to an intracranial neoplasm should be monitored routinely while on somatropin therapy for progression or recurrence of the tumor. Patients on somatropin therapy should be monitored carefully for increased growth, or potential malignant changes, of preexisting nevi. Because children with certain rare genetic causes of short stature have an increased risk of developing malignancies, these patients should be carefully monitored for development of neoplasms, if treatment with somatropin is initiated
  • Glucose intolerance and diabetes mellitus
  • Intracranial hypertension
  • Fluid retention
  • Patients with hypopituitarism should have their other hormonal replacement treatments closely monitored during somatropin treatment
  • Hypothyroidism
  • Slipped capital femoral epiphysis in pediatric patients
  • Progression of pre-existing scoliosis in pediatric patients
  • Otitis media and cardiovascular disorders in patients with Turner syndrome
  • Pancreatitis
  • Children with growth failure secondary to CKD should be examined periodically for evidence of progression of renal osteodystrophy
  • Injection site should be rotated to avoid tissue atrophy. Patients should be informed that local or systemic allergic reactions may occur and that prompt medical attention should be sought in such cases
  • Serum levels of inorganic phosphorus, alkaline phosphatase, parathyroid hormone and IGF-I may increase during somatropin therapy
  • Somatropin should be used during pregnancy only if clearly needed and with caution in nursing mothers because it is not known whether somatropin is excreted in human milk
  • Clinical studies of somatropin did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger patients
  • Somatropin inhibits 11ß-hydroxysteroid dehydrogenase type 1 (11ßHSD-1) in adipose/hepatic tissue and may significantly impact the metabolism of cortisol and cortisone. As a consequence, in patients treated with somatropin, previously undiagnosed central (secondary) hypoadrenalism may be unmasked, requiring glucocorticoid replacement therapy
  • Careful monitoring is advisable when somatropin is administered in combination with insulin and/or other hypoglycemic agents, other drugs metabolized by CYP450 liver enzymes (eg, hydrocortisone or other corticosteroids, sex steroids, anticonvulsants, cyclosporine), or other hormone replacement therapy

MOST COMMON ADVERSE REACTIONS

  • Common adverse reactions reported in adult and pediatric patients taking somatropin include injection site reactions. Additional common adverse reactions in adults include edema, arthralgia, and carpal tunnel syndrome.

You may report side effects to FDA at (800) FDA-1088 or www.fda.gov/medwatch.
You may also report side effects to Genentech at (888) 835-2555.

Please see accompanying full Prescribing Information for additional Important Safety Information.

Back to Top